Axitinib as Maintenance Treatment in Patients With Metastatic CRC
The purpose of this study is to evaluate the maintenance therapy with axitinib in patients with metastatic colorectal carcinoma
Colorectal Carcinoma
DRUG: axitinib|DRUG: placebo
progression-free survival, 4 years
overall survival, 4 years|overall response rate, 4 years|duration of disease response, 4 years|Adverse events, 4 years
The purpose of this study is to evaluate the maintenance therapy with axitinib in patients with metastatic colorectal carcinoma